"China Treatment Guidelines for Stage IV Primary Lung Cancer (2021 Edition)" released
Xinhua News Agency, Beijing, January 22 (Reporters Li Bin, Lin Miaomiao) In order to timely reflect the latest progress in the treatment of stage IV lung cancer at home and abroad, further standardize and improve the treatment level of stage IV lung cancer in China, and improve the prognosis of patients, Chinese Medical Doctor Association Oncologist The branch and the Medical Oncology Branch of the China Medical Care International Exchange Promotion Association organized experts to update the contents of the "China Treatment Guidelines for Stage IV Primary Lung Cancer (2020 Edition)" and formulated the "China Treatment Guidelines for Stage IV Primary Lung Cancer (2021 Edition) )”, the full text was published in the first issue of 2021 in the Chinese Journal of Oncology.
Primary lung cancer is the malignant tumor with the highest incidence and mortality in China.
The "Analysis Report on the Epidemiology of Malignant Tumors in China" shows that in 2015, there were about 787,000 new cases of lung cancer in China and about 631,000 deaths.
Due to high invasiveness and lack of effective early detection methods, more than half of lung cancer patients in China are in stage IV when they see a doctor.
Chemotherapy is the cornerstone of the treatment of stage IV lung cancer, but the effect is not good.
In recent years, with the development of molecular targeted therapy and immunotherapy, the treatment concept of stage IV lung cancer has been continuously updated, and the survival of patients has been greatly improved.
"China Treatment Guidelines for Stage IV Primary Lung Cancer (2021 Edition)" includes clinical manifestations, physical examination, auxiliary examinations (laboratory examination, imaging examination, endoscopy, etc.), pathological diagnosis, staging, treatment, and patients with stage IV lung cancer Seven parts of the follow-up.
"This year we have focused on updating the new developments in immunotherapy and targeted therapy." said Professor Shi Yuankai, deputy director of the National Cancer Center and deputy dean of the Chinese Academy of Medical Sciences Cancer Hospital.
The guidelines point out that pathological diagnosis is the gold standard for the diagnosis of lung cancer. Molecular classification based on genetic characteristics has enabled the treatment of stage IV lung cancer to enter the era of individualized molecular targeted therapy. In 2015, the World Health Organization published a new histological classification of lung tumors. One of the most important developments is the emphasis on molecular genetics in the individualized treatment strategies for patients with stage IV lung cancer.
"The treatment principle of stage IV lung cancer is based on systemic treatment based on multidisciplinary comprehensive treatment. Individualized treatment strategies can be formulated according to the patient's pathological type, molecular genetic characteristics and body state, which can maximize the survival time of the patient and control the progression of the disease. , Improve the quality of life." Shi Yuankai said.